Customization: | Available |
---|---|
CAS No.: | 736992-21-5 |
Formula: | Chons |
Still deciding? Get samples of US$ 1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Purity | 99%+ | Private customization | 2mg 5mg 10mg 15mg 20mg 30me etc. | |
Cleanliness | Sterile | Transportation time | 7-15days | |
Actual peptide content | Exceed the standard | Disguise | Can provide | |
Test Report | Janoshik Test Report | Resend policy | According to different countries | |
Customized top color | Red Yellow Blue Black Purple White Green | Payment method | Bank Transfer BTC USDT Paypal |
Elamipretide (also known as SS-31) is a novel mitochondrial-targeted peptide with immense promise as a therapeutic agent in mitochondrial dysfunction-related disorders. This research paper aims to provide a comprehensive analysis of Elamipretide, delving into its biochemical properties, mechanisms of action, and potential applications in various disease conditions.
Elamipretide, a mitochondria-targeting tetrapeptide, has garnered attention for its unique ability to protect mitochondria from oxidative stress and attenuate mitochondrial dysfunction (Siegel et al., 2013). This paper endeavors to explore Elamipretide's biochemical basis and its potential as a therapeutic agent in various diseases linked to mitochondrial impairment.
Elamipretide selectively accumulates within the inner mitochondrial membrane, where it exerts its cytoprotective effects. By reducing reactive oxygen species (ROS) production and enhancing electron transport chain efficiency, Elamipretide plays a crucial role in mitochondrial homeostasis (Kloner et al., 2015).
The mitochondrial protective actions of Elamipretide arise from its interaction with cardiolipin, a phospholipid predominantly localized in the inner mitochondrial membrane. By binding to cardiolipin, Elamipretide stabilizes mitochondrial cristae, improves membrane integrity, and enhances oxidative phosphorylation (Minkler et al., 2015).
Elamipretide's potential applications extend to a myriad of disease conditions characterized by mitochondrial dysfunction. In preclinical studies, Elamipretide has shown promise in mitigating tissue damage following ischemia-reperfusion injury, preserving cardiac function after myocardial infarction, and ameliorating neurodegenerative processes (Birk et al., 2017; Cho et al., 2015).
As the research on Elamipretide progresses, further investigation is warranted to better understand its pharmacokinetics, long-term safety, and potential off-target effects. Clinical trials exploring its therapeutic efficacy in human diseases offer exciting prospects for the future.
Elamipretide, a mitochondria-targeting peptide, emerges as a promising candidate in combating mitochondrial dysfunction-related disorders. Its unique ability to stabilize mitochondrial membranes and enhance cellular bioenergetics positions Elamipretide as a novel therapeutic option for a diverse range of diseases.
Peptides are composed of amino acids linked together by Peptides. The smallest Peptides can consist of three amino acids, such as thyrotropin-releasing hormone (TRH). Most Peptides can be made up of dozens or even hundreds of amino acids. The primary secretion organs for Peptides are the hypothalamus and the pituitary gland; however, Peptides have also been found in other organs, such as the gastrointestinal tract, brain tissue, lungs, and heart. Peptides are a type of endogenous substance that consists of protein chains containing polypeptide compounds. Examples of Peptides include thyrotropin-releasing hormone, Peptides and its analogs, Peptides and its analogs, adrenocorticotropic hormone, gonadotropins, Peptides and its analogs, Peptides-like Peptides, calcitonin, and parathyroid hormone.
1. How can I confirm the quality of the product before purchasing?